NEOS Investment Management LLC Buys 6,219 Shares of Zoetis Inc. (NYSE:ZTS)

NEOS Investment Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 30.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,386 shares of the company's stock after purchasing an additional 6,219 shares during the period. NEOS Investment Management LLC's holdings in Zoetis were worth $4,299,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ZTS. Moment Partners LLC bought a new position in Zoetis in the 4th quarter worth $374,000. Sava Infond d.o.o. bought a new position in shares of Zoetis in the fourth quarter worth about $1,980,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Zoetis by 4.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,664,867 shares of the company's stock worth $271,889,000 after purchasing an additional 68,249 shares during the period. Korea Investment CORP lifted its position in shares of Zoetis by 11.6% during the 4th quarter. Korea Investment CORP now owns 328,156 shares of the company's stock worth $53,466,000 after purchasing an additional 34,174 shares during the last quarter. Finally, Tyler Stone Wealth Management boosted its stake in Zoetis by 13.2% during the 4th quarter. Tyler Stone Wealth Management now owns 2,405 shares of the company's stock valued at $392,000 after purchasing an additional 281 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Remove Ads

Zoetis Price Performance

Zoetis stock traded down $0.14 during mid-day trading on Tuesday, hitting $164.51. 467,865 shares of the company were exchanged, compared to its average volume of 2,589,013. The company has a market capitalization of $73.67 billion, a PE ratio of 30.09, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a fifty day moving average of $166.37 and a 200 day moving average of $174.26.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZTS. Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and an average target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.